Search Results 1251-1260 of 17105 for monoclonal antibody

1. Discovery's Edge: Cleaning up cancer - Mayo Clinic News Network

   ... antibody to guide an established cancer drug to melanoma tumors. Dr. Markovic, whose background is biochemistry, packs several hundred of these antibodies ...

2. Publications - Timothy D. Wiltshire, Ph.D. - Mayo Clinic

   Antibodies as drugs-a Keystone Symposia report. ... Convalescent plasma with a high level of virus-specific antibody effectively neutralizes SARS-CoV-2 variants ...

3. Broad Evidence of Systemic Immune Activation in Long Term Survivors of Advanced Ovarian Cancer - Mayo Clinic

   ... antibody responses to folate receptor alpha and will have broad evidence of systemic immune activation. Participation eligibility. Participant eligibility ...

4. A Study to Evaluate Induction Chemotherapy with ABVD Followed by Brentuximab Vedotin Consolidation in Previously-untreated, Non-bulky Stage I or II Hodgkin Lymphoma - Mayo Clinic

   For this research study, the use of brentuximab vedotin in newly diagnosed Hodgkin lymphoma is considered investigational. Brentuximab vedotin is an antibody ...

5. Oncology (Medical) - Clinical trials - Mayo Clinic

   The purpose of this study is to evaluate the immune and hematopoietic compartments in patients with monoclonal B cell lymphocytosis (MBL) and chronic ...

6. A Study to Evaluate the Effectiveness and Safety of Oral OPS-2071 in Subjects With Crohn's Disease Showing Symptoms of Active Inflammation - Mayo Clinic

   ... monoclonal antibody), immunosuppressants, low-dose steroids, or 5-aminosalicylic acid (5-ASA) formulations. Subjects who are on stable Crohn's disease ...

7. PTT-936, an Alpha Kinase 1 (ALPK1) Activator, Alone or in Combination with Anti-PD-1/L1 in Patients with Locally Advanced or Metastatic Solid Tumors - Mayo Clinic

   Treatment with commercially available or investigational large molecule cancer therapies, including monoclonal antibodies (mAbs), bispecific antibodies, ...

8. Exploring the Role of B-cell Activating Factor Receptor (BAFFR)-based Chimeric Antigen Receptor T-cell (CAR T) in BAFFR-expressing B-cell Hematologic Malignancies and Autoimmune Rheumatologic Disorders - Mayo Clinic

   ... antibody (ANCA) associated vasculitis using primary samples and/or patient derived xenograft models. Participation eligibility. Participant eligibility ...

9. Everolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma - Mayo Clinic

   Patients who have received any continuous or intermittent small molecule therapeutics (excluding monoclonal antibodies) ≤ 5 effective half-lives prior to ...

10. Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer - Mayo Clinic

    Monoclonal antibodies =< 2 weeks; Radiation therapy =< 2 weeks; Anti-Her-2 or other "targeted" (e.g. mammalian target of rapamycin [mTOR]) therapy =< 2 weeks.